Research Study for Children with Growth Hormone Excess



Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health (NIH) want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.

Study Design:

- All visits include medical history, physical exam, & questionnaires
- Participants will have regular blood tests and imaging studies
- All study-related evaluations and medications are free
- Travel and lodging assistance will be provided

Who can participate?

- People 2 -18 years old* with GH excess for whom surgical treatment has not worked or who are not eligible for that
- Insulin-like growth factor-1 (IGF-1) greater than the upper limit of normal for age and gender
- Elevated growth hormone levels
- Not currently taking other medications for the management of growth hormone excess

The NIH Clinical Center, America's Research Hospital, is located on the Metro Red Line (Medical Center stop) in Bethesda, Maryland

Office of Patient Recruitment 1-800- 411-1222

TTY for the deaf and hard of hearing: 1-866-411-1010
Email: prpl@cc.nih.gov
Online: https://go.usa.gov/xyqQu
(Refer to study # 19-CH-0071)





^{*} Parents must give permission for minors to participate.